StockData
Pulmonx Corp logo

Pulmonx Corp (LUNG) company profile

LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3042% below fair value
$2.80−0.06 (-2.10%)

Close on Nov 16, 2026Market cap $120.26MP/E –Yield –

About Pulmonx

Surgical & Medical Instruments & Apparatus, SIC 3841

The company is a commercial-stage medical technology business that develops and provides minimally invasive treatments for patients suffering from severe emphysema, a form of chronic obstructive pulmonary disease. Its core solution combines the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX cloud-based analysis platform. In addition, the business manufactures the AeriSeal System, an investigational synthetic polymer foam designed to close collateral air channels in targeted lung lobes. The enterprise primarily sells its products directly to hospital customers, while focusing its sales and educational initiatives on interventional pulmonologists performing pulmonary procedures.

The business commercializes its products internationally across North America, Europe, and the Asia Pacific region, maintaining market access in countries such as the United States, Australia, Austria, Belgium, France, Germany, Japan, the Netherlands, South Korea, Switzerland, and the United Kingdom. It relies on a direct sales force in principal markets alongside distributor networks in smaller or emerging territories. The provided text does not state the location of the company's headquarters.

Summary of the business section of Pulmonx's latest annual report, written by StockData.

Company profile

Company

Legal name
Pulmonx Corp
Founded
1998
Headquarters
Redwood City, CA
Address
700 Chesapeake Drive 94063
Phone
(650) 364-0400
Employees
296, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Francisco, California

Stock & identifiers

Ticker
LUNG
Exchange
Nasdaq
IPO date
Oct 1, 2020
Shares outstanding
43M, Jul 31, 2026
Public float
$101.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1127537
CUSIP
745848101
ISIN
US7458481014
FIGI
BBG000LZVJC9
Share class FIGI
BBG001T4HJ52
LEI
549300WZMFR0ZK7RJY40
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Glendon E. French IIIPresident and CEO, Director2,056,134
Steven S. WilliamsonPRESIDENT AND CEO, Director363,497
David Aaron LehmanGeneral Counsel370,130
Srikanth RadhakrishnanChief Science & Techn. Officer326,475
Geoffrey Beran RoseChief Commercial Officer453,108
Derrick SungCOO and CFO1,335,319
Mehul JoshiChief Financial Officer & PAO208,489
Thomas William BurnsDirector113,399
Richard FerrariDirector1,359,345
Georgia MelenikiotouDirector139,714
Dana G. Mead Jr.Director143,790
Daniel P. FlorinDirector149,699
Tiffany SullivanDirector115,199

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Glendon EFrench
$3.54M$2.93M$2.22M$3–
FY2025
Steven SWilliamson
$4.20M$1.10M$2.22M$3–
FY2024
Glendon EFrench
$330.79K-$2.38M$2.36M$10–
FY2024
Steve Williamson
$5.23M$4.16M$2.36M$10–
FY2024
Steven SWilliamson
$5.23M$4.16M$2.36M$10–
FY2023$5.80M$8.21M$2.42M$18–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Glendon E. French
Chief Executive Officer
$116.19K–$3.22M––$153.33K$3.54M+971%
Steven S. Williamson
Former Chief Executive Officer
$493.46K–$2.26M$752.38K–$691.18K$4.20M-20%
Derrick Sung
Chief Operating Officer and Chief Financial Officer
$83.33K$200.00K$2.67M––$58$2.95M–
Mehul Joshi
Former Chief Financial Officer
$381.20K–$1.19M––$408.80K$1.98M-39%
David Lehman
General Counsel
$472.40K–$1.19M–$43.79K$452$1.71M+15%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 1, 2020
Offer price
$19.00
Securities offered
10,000,000
Gross proceeds
$190.00M
Exchange
Nasdaq
First trading day
Oct 1, 2020
First-day close
$39.31+106.9%
Lock-up ends (est.)
Mar 30, 2021

“The initial public offering price per share of our common stock is $19.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 296 full time employees, with 229 employees in the U.S., 56 in Europe, and 11 in Asia Pacific.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 1, 2020IPOInitial public offering priced (424B4 prospectus)
Sep 24, 2020ListingRegistration of securities on an exchange (Form 8-A)
Feb 7, 2012Name changeName changed from PULMONX to Pulmonx Corp

See a number that looks wrong?